MDACC Study No:2012-0588 ( NCT No: NCT01656642)
Title:A Phase Ib, Open-Label Study of the Safety and Pharmacology of MPDL3280A Administered in Combination with Vemurafenib in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Principal Investigator:Patrick Hwu
Treatment Agent:MPDL3280A; Vemurafenib
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of MPDL3280A that can be given in combination with vemurafenib (Zelboraf®) to
patients with locally advanced or metastatic melanoma that has a BRAF
mutation. The safety of the drug combination will also be studied.

MPDL3280A is designed to help the immune system recognize the tumors and may
help stop the their growth.

Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer cells to grow and multiply. By blocking this mutation, the drug may
kill the cancer cells with the mutation and/or stop the tumor from growing.

Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:MPDL3280A
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Patrick Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults